GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (WAR:RVU) » Definitions » Beneish M-Score

Ryvu Therapeutics (WAR:RVU) Beneish M-Score : -0.02 (As of Jun. 23, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Ryvu Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.02 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Ryvu Therapeutics's Beneish M-Score or its related term are showing as below:

WAR:RVU' s Beneish M-Score Range Over the Past 10 Years
Min: -10.7   Med: -0.61   Max: 20.54
Current: -0.02

During the past 13 years, the highest Beneish M-Score of Ryvu Therapeutics was 20.54. The lowest was -10.70. And the median was -0.61.


Ryvu Therapeutics Beneish M-Score Historical Data

The historical data trend for Ryvu Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ryvu Therapeutics Beneish M-Score Chart

Ryvu Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.96 -4.32 1.85 -2.74 1.72

Ryvu Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.86 - -1.10 1.72 -0.02

Competitive Comparison of Ryvu Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Ryvu Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ryvu Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Ryvu Therapeutics's Beneish M-Score falls into.



Ryvu Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Ryvu Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8866+0.528 * 0.9403+0.404 * 1.1238+0.892 * 1.074+0.115 * 1.0551
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * -16.3876+4.679 * 0.001489-0.327 * 2.611
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was zł21.41 Mil.
Revenue was 21.606 + 11.195 + 12.045 + 10.759 = zł55.61 Mil.
Gross Profit was 16.76 + 6.232 + 8.813 + 6.307 = zł38.11 Mil.
Total Current Assets was zł293.88 Mil.
Total Assets was zł404.84 Mil.
Property, Plant and Equipment(Net PPE) was zł75.80 Mil.
Depreciation, Depletion and Amortization(DDA) was zł10.95 Mil.
Selling, General, & Admin. Expense(SGA) was zł18.74 Mil.
Total Current Liabilities was zł61.93 Mil.
Long-Term Debt & Capital Lease Obligation was zł26.13 Mil.
Net Income was -19.399 + -27.754 + -18.254 + -28.507 = zł-93.91 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = zł0.00 Mil.
Cash Flow from Operations was -43.235 + -19.483 + -7.171 + -24.628 = zł-94.52 Mil.
Total Receivables was zł22.48 Mil.
Revenue was 12.861 + 24.619 + 14.264 + 0.031 = zł51.78 Mil.
Gross Profit was 7.955 + 19.467 + 10.537 + -4.59 = zł33.37 Mil.
Total Current Assets was zł334.38 Mil.
Total Assets was zł449.18 Mil.
Property, Plant and Equipment(Net PPE) was zł80.09 Mil.
Depreciation, Depletion and Amortization(DDA) was zł12.31 Mil.
Selling, General, & Admin. Expense(SGA) was zł-1.07 Mil.
Total Current Liabilities was zł36.73 Mil.
Long-Term Debt & Capital Lease Obligation was zł0.69 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(21.406 / 55.605) / (22.48 / 51.775)
=0.384965 / 0.434186
=0.8866

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(33.369 / 51.775) / (38.112 / 55.605)
=0.6445 / 0.685406
=0.9403

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (293.879 + 75.802) / 404.835) / (1 - (334.381 + 80.093) / 449.183)
=0.086835 / 0.077271
=1.1238

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=55.605 / 51.775
=1.074

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(12.307 / (12.307 + 80.093)) / (10.952 / (10.952 + 75.802))
=0.133193 / 0.126242
=1.0551

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(18.744 / 55.605) / (-1.065 / 51.775)
=0.337092 / -0.02057
=-16.3876

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((26.134 + 61.934) / 404.835) / ((0.691 + 36.734) / 449.183)
=0.21754 / 0.083318
=2.611

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-93.914 - 0 - -94.517) / 404.835
=0.001489

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Ryvu Therapeutics has a M-score of -0.02 signals that the company is likely to be a manipulator.


Ryvu Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Ryvu Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Ryvu Therapeutics (WAR:RVU) Business Description

Traded in Other Exchanges
N/A
Address
Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.

Ryvu Therapeutics (WAR:RVU) Headlines

No Headlines